| 前收市價 | 41.30 |
| 開市 | 無 |
| 買盤 | 106.80 |
| 賣出價 | 109.90 |
| 拍板 | 145.00 |
| 到期日 | 2024-12-20 |
| 今日波幅 | 41.30 - 41.30 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 2 |
ZacksAlnylam (ALNY) Soars as Heart Disease Drug Study Meets Goals
Alnylam (ALNY) soars as its phase III study, seeking to expand Anvuttra's label to include the treatment of ATTR amyloidosis with cardiomyopathy, achieves primary and all secondary endpoints.
Investor's Business DailyAlnylam Skyrockets After Hitting A 'Best-Case Scenario' For Heart Drug
Alnylam stock catapulted Monday after its experimental heart-disease treatment topped expectations in a highly anticipated study.
Barrons.comAlnylam Stock Pops on Surprising Results From a Key Heart Disease Drug
The drugmaker says the study met the primary endpoint and demonstrated significant improvements across all secondary endpoints.
